11月10日 - ** 上周五晚些时候，一场激烈的制药商竞购战结束，美赛拉MTSR.O股价盘前大跌15.7%，至70.12美元。
** MTSR接受辉瑞PFE.N的100亿美元收购要约 (link)，联合竞购者诺和诺德NOVOb.CO表示将退出竞购
** 辉瑞同意支付每股86.25美元的现金，比美塞拉周五收盘价上涨3.69
** 美塞拉接受了辉瑞的更高报价，理由是诺和诺德的出价中存在 "不可接受的高法律和监管风险
** 伯恩斯坦认为辉瑞100亿美元的估值过于乐观，到2040年需要110亿美元的收入
** 在竞购战中，MTSR 股价上周大涨近 60
** 自今年 1 月上市以来，MTSR 的股价已上涨了三倍多，而截至上次收盘，辉瑞的股价则下跌了 7.82%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.